SynthesisJournal of radiation research2025
Stereotactic body radiotherapy with CyberKnife for liver-confined hepatocellular carcinoma: systematic review and meta-analysis.
Synthesis in Journal of radiation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CyberKnife SBRT plus lenvatinib and tislelizumab versus doublet systemic therapy for hepatocellular carcinoma with macrovascular invasion: A real-world IPTW-adjusted study.Clinical and translational radiation oncology · 2027Article
- Stereotactic body radiotherapy using the CyberKnife system for cutaneous metastasis of hepatocellular carcinoma: a case description.Quantitative imaging in medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this systematic review and meta-analysis was to evaluate the efficacy and safety of stereotactic body radiotherapy using CyberKnife (CK) for liver-confined hepatocellular carcinoma (HCC). A systematic review was performed on studies published between 2000 and 2024 that reported treatment outcomes including overall survival (OS), local control (LC), and complications. A literature search was performed using MEDLINE/PubMed with the following terms: ('Carcinoma, Hepatocellular'[MeSH Terms] OR 'hepatocellular carcinoma' OR 'HCC') AND ('CyberKnife' OR 'robotic radiosurgery'). Additional searches were conducted on Scopus and the Cochrane library using following terms: 'Hepatocellular carcinoma' AND 'CyberKnife.' A meta-analysis was performed to assess OS and LC using weighted random effects models. Five retrospective studies and one prospective study were included in the meta-analysis, comprising a total of 697 patients with a median follow-up duration was 31 months (range: 15-48 months). The pooled 3-year LC and OS rates were 82.5% (95% confidence interval [CI], 75.0%-90.0%) and 58.7% (95% CI, 47.2%-70.1%), respectively, which is comparable to previous reported outcomes for non-device-limited SBRT and similar to that of surgery and local ablative therapies. The incidence of radiation-induced liver disease was 4.3%-15.3%. Stereotactic body radiotherapy using CK appears to be an effective and well-tolerated treatment for liver-confined HCC. However, further prospective studies with standardized methodologies are warranted to establish solid evidence of its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.